PCSK9 inhibitors for high cholesterol: the honest evidence for the injectable LDL-lowering drugs

What PCSK9 inhibitors actually are

PCSK9 stands for proprotein convertase subtilisin/kexin type 9 — a protein your liver makes that, left to its own devices, quietly sabotages your ability to clear cholesterol. The drugs that block it are among the most powerful LDL-lowering agents ever brought to market. LDL-C here means low-density lipoprotein cholesterol, the “bad cholesterol” number that decades of trials have tied causally to atherosclerotic cardiovascular disease (ASCVD) — the plaque-driven process behind most heart attacks and ischemic strokes.

There are three of them in wide use, and they come in two flavors. Two are monoclonal antibodies — a mAb is a lab-engineered antibody designed to bind one specific target — evolocumab (brand name Repatha) and alirocumab (Praluent), injected under the skin every two to four weeks. The third, inclisiran (Leqvio), is a small interfering RNA drug — siRNA is a short piece of genetic material that silences the gene that codes for PCSK9 — and it is injected only twice a year after the initial doses. All three do the same downstream thing: they leave more of your liver’s LDL receptors free to pull cholesterol out of your blood.

The mechanism: recycling the LDL receptor

To see why blocking one protein produces such a large LDL drop, you have to follow the LDL receptor. Your liver cells stud their surface with LDL receptors, which grab LDL particles out of the bloodstream and pull them inside to be broken down. Normally that receptor gets recycled — it releases its cargo and returns to the surface to catch another particle, over and over. The more receptors working the door, the lower your blood LDL.

PCSK9 is the wrench in that machine. It binds to the LDL receptor and marks it for destruction, so instead of being recycled the receptor is dragged inside the cell and degraded. High PCSK9 activity means fewer receptors on the surface, which means less LDL cleared and higher blood cholesterol. This is not a theory pieced together from cell lines — people born with loss-of-function mutations in PCSK9 have strikingly low LDL and strikingly low rates of heart disease, which is exactly the natural experiment that made the protein a drug target in the first place.⁶

The drugs exploit that. Block PCSK9 — whether by mopping up the circulating protein with an antibody or by shutting down its production with siRNA — and the LDL receptors stop getting destroyed. They stay on the cell surface, keep recycling, and clear far more LDL from the blood. Layered on top of a statin (which itself works partly by increasing LDL-receptor numbers), the effect is additive and large: an extra 50 to 60 percent reduction in LDL-C, routinely driving patients to levels below 40 mg/dL that no statin dose alone could reach.¹⁶ That magnitude of LDL lowering is the single most reliable, best-replicated fact about this drug class — and it is why the mechanism claim earns a STRONG grade.

PCSK9 inhibitors don’t give your liver a new tool. They stop it from throwing away the one it already has — the receptor that pulls cholesterol out of your blood.

Three drugs, two mechanisms

Evolocumab (Repatha) and alirocumab (Praluent) are the monoclonal antibodies. They physically bind free PCSK9 in the bloodstream so it can’t reach the LDL receptor. Because antibodies get cleared over days to weeks, they are dosed frequently — typically a subcutaneous injection every two weeks, or a larger monthly dose. Patients self-administer with an autoinjector pen. These are the two drugs with completed cardiovascular-outcomes trials, so they carry the strongest evidence base — evolocumab’s durable LDL lowering was first shown in the long-term open-label OSLER program before FOURIER confirmed the event benefit.⁴

Inclisiran (Leqvio) takes a different road to the same destination. Rather than intercepting PCSK9 after it’s made, the siRNA drug targets the messenger RNA that tells liver cells to build PCSK9 in the first place, silencing production at the source. The practical payoff is dosing convenience that the antibodies can’t match: after an initial dose and one at three months, inclisiran is injected only twice a year. For a chronic, symptom-free condition where people forget or abandon daily and biweekly regimens, a twice-yearly clinic visit is a genuinely different adherence proposition. The LDL lowering is comparable — roughly 50 percent — but as we’ll see, comparable LDL lowering is not yet the same as comparable proof of fewer heart attacks.

What the outcomes trials showed

Lowering a number is not the same as preventing an event, and this class earned its place precisely because it was tested against hard endpoints in randomized controlled trials (RCTs). Two matter most.

FOURIER (2017) randomized more than 27,000 patients with established atherosclerotic cardiovascular disease, all already on statin therapy, to evolocumab or placebo. Evolocumab drove median LDL-C down to about 30 mg/dL — a 59 percent reduction — and cut the primary composite endpoint of major cardiovascular events. The hazard ratio (HR, the ratio of event rates between groups) was 0.85, meaning a 15 percent relative risk reduction (RRR) over a median of 2.2 years.¹ Importantly, FOURIER showed no significant reduction in all-cause mortality — the benefit was in nonfatal heart attacks and strokes and revascularizations, not in deaths, over that follow-up.

ODYSSEY OUTCOMES (2018) tested alirocumab in nearly 19,000 patients who had recently survived an acute coronary syndrome. Same headline: a 15 percent relative reduction in the primary composite endpoint (HR 0.85) over a median 2.8 years.² But ODYSSEY added something FOURIER didn’t: a signal toward lower all-cause mortality in the alirocumab group. That difference — a possible mortality benefit in one antibody trial and not the other — is one of the genuinely unsettled questions in the field, likely driven by differences in the populations, follow-up length, and trial design rather than a true gap between the two drugs.

The consistency across two large, independent RCTs — two different antibodies, two different high-risk populations, the same 15 percent relative reduction — is what earns the event-reduction claim a STRONG grade. This is not a single-trial fluke.

Relative vs absolute: the number that matters

This is where honesty separates from marketing, and it’s the same trap that makes statin conversations go sideways. A “15 percent reduction in cardiac events” sounds enormous. But that is the relative risk reduction (RRR) — the proportional shrinkage between two rates. What actually determines how much a given patient benefits is the absolute risk reduction (ARR) — the raw difference in the percentage of people who had an event.

In FOURIER, the primary endpoint occurred in about 9.8 percent of the evolocumab group versus 11.3 percent of the placebo group. That’s a 15 percent relative reduction, but only a roughly 1.5 percentage-point absolute reduction over 2.2 years.¹ Put another way, you would need to treat dozens of high-risk patients for a couple of years to prevent one event. That is not nothing — in a high-risk population with millions of people, it adds up to a lot of prevented heart attacks — but it is a far cry from the impression “cuts your risk 15 percent” leaves in most people’s heads. ODYSSEY’s absolute numbers were similar in scale.²

Two further caveats keep the picture honest. First, these were relatively short trials; the benefit of LDL lowering compounds over time, so lifetime benefit is plausibly larger than a two-to-three-year snapshot suggests — but that is an extrapolation, not a measured result. Second, and most important, everyone in these trials was already on a statin. PCSK9 inhibitors were tested as an add-on to statin therapy in patients who remained above goal, not as a substitute for it. That framing is the whole ballgame for who should get one. We walk through the same relative-versus-absolute distinction in our companion piece on how statin benefits look once you convert them to absolute numbers, which is essential context for reading these figures.

Inclisiran: the twice-a-year question mark

Inclisiran’s pitch is adherence, and on LDL lowering it delivers. The pivotal ORION-10 and ORION-11 trials, published together in 2020, randomized patients with atherosclerotic cardiovascular disease (or risk equivalents) and elevated LDL despite maximally tolerated statins to inclisiran or placebo. With injections at day 1, month 3, and then every six months, inclisiran produced placebo-corrected LDL-C reductions of roughly 50 percent, sustained across the dosing interval.³ For a drug you take twice a year, that is a striking result.

But here is the honest limit, and why inclisiran earns an EMERGING grade rather than a STRONG one. ORION-10 and ORION-11 were LDL-lowering trials, powered to measure cholesterol, not heart attacks. They were not designed to prove that inclisiran prevents cardiovascular events. The large cardiovascular-outcomes trial built to answer that question (the ORION-4 program) was still running and reporting as of this writing. So with inclisiran we are relying on the well-established principle that lowering LDL lowers risk — a principle backed by decades of statin and antibody data — rather than on direct hard-endpoint proof for this specific drug. That is a reasonable inference, and regulators accepted it, but it is not the same evidentiary footing as FOURIER and ODYSSEY. Anyone telling you inclisiran is “proven” to prevent heart attacks the way the antibodies are is getting ahead of the data.

Who they’re actually for

Strip away the enthusiasm and the guidelines draw a fairly tight circle. The 2018 AHA/ACC cholesterol guideline and the outcomes-trial populations point to three groups where PCSK9 inhibitors make the most sense.⁵

Very high-risk secondary prevention not at goal. The core population: someone who already has established atherosclerotic disease — a prior heart attack, stroke, or symptomatic peripheral artery disease — and whose LDL-C remains above target (often cited as 70 mg/dL, sometimes lower for the highest-risk) despite maximally tolerated statin therapy, usually with ezetimibe added. This is exactly who FOURIER and ODYSSEY enrolled, and where the proven benefit lives.

Familial hypercholesterolemia (FH). FH is a genetic condition — often involving the LDL receptor or PCSK9 itself — that produces lifelong, extremely high LDL and early heart disease. These patients frequently can’t reach goal on statins alone no matter the dose, and the profound LDL lowering PCSK9 inhibitors provide is often the difference between controlled and uncontrolled.

Genuine statin intolerance. For the smaller number of patients who truly cannot tolerate statins — not the far more common nocebo-driven muscle complaints that resolve on rechallenge, but real, reproducible intolerance — a PCSK9 inhibitor can lower LDL substantially without a statin backbone. But note the nuance: the trials proving events were run on top of statins, so using these drugs as a solo replacement rests on weaker outcomes evidence than using them as an add-on.

What ties all three together is that these are not first-line drugs and not for mild or moderate hypercholesterolemia in low-risk people. The absolute benefit — and therefore the value for money — is concentrated in people whose baseline risk is high. In a low-risk person, a 15 percent relative reduction on an already-small risk buys almost nothing in absolute terms. For a broader map of where cholesterol drugs sit relative to one another, our pharmaceuticals hub collects the same evidence-first treatment for the rest of the cardiometabolic toolkit.

Safety and the neurocognitive scare

On tolerability, PCSK9 inhibitors have been a pleasant surprise. Across the large trials they were generally well tolerated, with the most common complaint being injection-site reactions — redness, itching, or mild pain where the needle goes in — which were usually minor. Unlike statins, they don’t carry a muscle-symptom or liver-enzyme signal, and they don’t raise blood sugar.

The one scare worth addressing head-on is cognition. Because these drugs push LDL to unprecedented lows, some worried that starving the brain of cholesterol might harm memory or thinking. That question was tested directly. The EBBINGHAUS substudy of FOURIER put patients through formal, repeated cognitive testing and found no significant difference in cognitive function between evolocumab and placebo, even in patients who reached very low LDL levels.⁷ That is a reassuring, dedicated dataset — not just an absence of complaints, but a study built to look for the harm and not finding it.

The honest caveats: the outcomes trials ran a few years, so the very-long-term safety of sustained ultra-low LDL over decades is an extrapolation rather than a measured fact, and antibody drugs carry a small potential for injection reactions and, rarely, immune responses. But within the studied range, the safety profile is a genuine strength of this class — which is why the safety claim lands at MODERATE, held there mainly by the limited long-term horizon rather than by any red flag in the data.

Cost and access reality

The evidence story and the access story have historically diverged. When the antibodies launched, list prices in the range of roughly 14,000 US dollars a year triggered a wave of insurer prior-authorization hurdles and high rejection rates — ironic for drugs that work, but a rational response to a modest absolute benefit at a steep price. Cost-effectiveness analyses at launch prices frequently found the drugs poor value except in the highest-risk patients, and manufacturers subsequently cut prices substantially, which improved access.

Even so, cost and coverage remain a real barrier, and it shapes who actually gets these drugs as much as the clinical guidelines do. Inclisiran’s twice-yearly, clinic-administered model was pitched partly as a way around adherence problems and, in some health systems, around the pharmacy-benefit friction that dogged the antibodies. The practical reality in 2026 is that eligibility, prior authorization, and out-of-pocket cost vary widely by country and plan, and getting one approved often means documenting maximal statin therapy and a still-elevated LDL first. None of this is medical advice about your coverage — it’s context for why a proven drug still isn’t simply handed out.

What this article is not saying

This is not “PCSK9 inhibitors don’t work.” They are among the most effective LDL-lowering drugs ever made, and two large randomized trials proved they cut cardiovascular events in high-risk patients. For someone with familial hypercholesterolemia or established heart disease who can’t reach goal on a statin, they can be genuinely life-changing. Dismissing them is as wrong as overselling them.

This is not “PCSK9 inhibitors are for everyone with high cholesterol.” That’s the HYPE claim, and it fails on the evidence. They are add-ons for a defined high-risk group, not a first-line drug, not a statin replacement, and not remotely worth the cost in low-risk people whose absolute benefit rounds to near zero. The idea that they make statins obsolete inverts the actual trials, every one of which was run on a statin backbone.⁵ And inclisiran’s convenience should not be mistaken for equivalent hard-outcome proof — its LDL data is strong, its event data is still maturing.³

And this is not a treatment recommendation. Every figure here describes what published trials reported, not what you should take. These are prescription drugs with real cost and a benefit that depends heavily on your individual risk. Whether one belongs in your regimen is a decision for you and a physician who knows your full picture — your lipid panel, your history, your other medications, and your goals. The point of this piece is to tell you what the trials show and exactly where they stop, so that conversation can be an honest one. For a related look at how off-label enthusiasm can outrun evidence in another drug class, see our read on low-dose naltrexone.